Literature DB >> 6853130

Hepatic lesions in patients on anabolic androgenic therapy.

H Turani, J Levi, D Zevin, E Kessler.   

Abstract

The histopathological changes in the livers of 11 patients treated with alkylated and nonalkylated anabolic androgenic steroids are presented. The histological changes in the liver included: proliferation of the bile ducts with or without cystic dilatation (9/11), peliosis (8/11), atypical hyperplasia of liver cells (2/11), and tumors (3/11). The latter included one case of cholangiocarcinoma, one of hepatocellular carcinoma, and one of combined cholangiocellular and hepatocellular carcinoma. The pathological changes in the liver in this series suggest a possible relationship between anabolic androgenic steroids and bile duct proliferation and/or cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853130

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  8 in total

Review 1.  Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature.

Authors:  A Kosaka; H Takahashi; Y Yajima; M Tanaka; K Okamura; R Mizumoto; K Katsuta
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

2.  Reversal of liver damage due to long term methyltestosterone and safety of non-17 alpha-alkylated androgens.

Authors:  C P Lowdell; I M Murray-Lyon
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-07

3.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

4.  Androgenic steroid effects on liver and red cells.

Authors:  M Alén
Journal:  Br J Sports Med       Date:  1985-03       Impact factor: 13.800

Review 5.  Adverse effects of anabolic steroids.

Authors:  R C Hickson; K L Ball; M T Falduto
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

6.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.

Authors:  Christin N Snyder; Richard V Clark; Ralph B Caricofe; Mark A Bush; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2010-04-08

7.  Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.

Authors:  M Y Roth; R E Dudley; L Hull; A Leung; P Christenson; C Wang; R Swerdloff; J K Amory
Journal:  Int J Androl       Date:  2010-10-24

Review 8.  Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics.

Authors:  Miren García-Cortés; Mercedes Robles-Díaz; Aida Ortega-Alonso; Inmaculada Medina-Caliz; Raul J Andrade
Journal:  Int J Mol Sci       Date:  2016-04-09       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.